Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$1.00
-$0.13(-5.94%)
At close: 4:00 PM EST
$1.00
-$0.13(-5.94%)
Day’s Range― - ―
52-Week Range$0.19 - $2.48
Previous CloseN/A
Volume74.29K
Average Volume (3M)14.35M
Market Cap
$3.50M
Enterprise Value$12.13
Total Cash (Recent Filing)$4.61M
Total Debt (Recent Filing)$4.88M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding17,375,990
10 Day Avg. Volume1,241,819
30 Day Avg. Volume14,347,656
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.63Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Gross Margin ExpansionA near 70% gross margin reflects strong unit economics for Tenon’s SI joint implants. Durable high margins indicate scalable production and pricing power as procedure volumes grow, allowing incremental revenue to flow to operating leverage and improving path to long‑term profitability.
Revenue Growth & Commercial TractionRapid top‑line growth and improving TTM revenue reflect accelerating surgeon adoption and product contribution from acquisitions. Sustained volume gains, expanded training and a field sales hire point to durable commercial momentum that can compound over 2–6 months as procedures scale and recurring implant demand rises.
IP And Product PipelineA growing patent portfolio plus staged product rollouts (Symmetry Plus enhancements and a new approach in 2027) create structural differentiation. Expanded IP and multiple commercialization catalysts strengthen competitive barriers and support longer‑term market share gains if execution proceeds as planned.
Bears Say
Persistent Cash BurnSignificant negative operating and free cash flow imply the business cannot self‑fund near‑term growth. Ongoing cash burn increases dependence on external financings, limits runway without additional capital, and raises dilution and refinancing risk that materially affects strategic flexibility over the next several quarters.
Elevated Leverage & Balance Sheet RiskA debt position materially larger than equity weakens financial resilience and raises servicing obligations. Higher leverage constrains investment choices, increases vulnerability to financing cost shocks, and contributed to prior Nasdaq deficiency — a structural risk until sustained profitability rebuilds equity.
Execution Reliance & Cost BaseMeaningful improvement depends on successful product launches, converting trained physicians into routine users, and easing facility access. With OpEx sizable relative to current revenue, any launch delays or slow conversion will prolong losses and pressure margins, making execution risk a core structural concern.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $0.19 and its highest was $2.48 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $3.50M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.305 by -$0.005.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 17,375,990 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.305. Following the earnings report the stock price went down -11.548%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
TNON Stock 12 Month Forecast
Average Price Target
$2.63
▲(162.50% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
8.78% Insiders
0.77% Mutual Funds
0.66% Other Institutional Investors
89.38% Public Companies and
Individual Investors